Arch Biopartners Inc
XTSX:ARCH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Arch Biopartners Inc
Total Receivables
Arch Biopartners Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Total Receivables
CA$6.8k
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-16%
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Total Receivables
$153.4m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Total Receivables
CA$1k
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Total Receivables
CA$907.2k
|
CAGR 3-Years
66%
|
CAGR 5-Years
45%
|
CAGR 10-Years
31%
|
|
Arch Biopartners Inc
Glance View
Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.
See Also
What is Arch Biopartners Inc's Total Receivables?
Total Receivables
6.8k
CAD
Based on the financial report for Dec 31, 2025, Arch Biopartners Inc's Total Receivables amounts to 6.8k CAD.
What is Arch Biopartners Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
-16%
Over the last year, the Total Receivables growth was -99%. The average annual Total Receivables growth rates for Arch Biopartners Inc have been -77% over the past three years , -45% over the past five years , and -16% over the past ten years .
